ArticleACR open rheumatology2026
Herpes Zoster Vaccine Uptake Among United States Adults With Rheumatic Disease: A Mixed-Methods Analysis.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Vaccination considerations in autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2026Review
- Review
- Coverage and Drivers of Vaccinations in Patients with Autoimmune Rheumatic Diseases: An Italian Multicentric Study.Vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveAdults with rheumatic diseases are at increased risk for herpes zoster (HZ). Recommendations for the recombinant zoster vaccine (RZV) were expanded in 2021 to include those aged ≥19 years at increased risk for HZ due to immunodeficiency or immunosuppression because of disease or therapy, but the impact of these expanded recommendations is unclear. This study assessed the impact of the updated recommendations on RZV uptake among adults with rheumatic disease in the US.
methodsA retrospective cohort analysis used open-source claims data to estimate RZV uptake, series completion, and dosing schedule compliance among unvaccinated adults with rheumatic disease from October 2021 to June 2023. Interviews with rheumatologists were conducted and thematically analyzed to characterize RZV vaccination practices related to managing patients with rheumatic disease.
resultsRZV uptake among adults with rheumatic disease and without prior RZV over the 20-month period following the updated recommendations was gradual (7.0%-10.4% across conditions) and low, and was particularly less likely among adults <50 years of age. The odds of RZV uptake were higher among those of older age, those with a household income greater than or equal to $50,000, and those of a non-White race or ethnicity. Financial concerns, lack of formal processes for tracking vaccination records and delivering reminders, and insufficient education and awareness were key barriers to RZV vaccination according to rheumatologists.
conclusionRZV uptake among adults with rheumatic disease has gradually increased, and opportunities to improve HZ prevention exist, some of which may be addressed through targeted educational efforts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.